Return to homepagePandemic Pact

Inhibitors of SARS-Coronavirus-2 infection / Consortium: iCoin

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2022

  • Known Financial Commitments (USD)

    $1,842,154.64

  • Funder

    Academy of Finland

  • Principal Investigator

    Olli Vapalahti

  • Research Location

    Finland

  • Lead Research Institution

    University of Helsinki

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Pharmaceutical interventions to decrease COVID-19 severity and lethality are urgently needed globally. Our multidisciplinary consortium is focused to develop therapies for COVID-19 at University of Helsinki and VTT using different approaches: by cloning and producing human antibodies cloned from individual immune cells from the patients recovered from COVID-19 disease, and by screening safe-in-human compounds for SARS-CoV-2 inhibitory effects in in vitro systems. Structural studies will produce information of SARS-CoV-2 binding at the molecular level, informing also further engineering of the binding antibodies. Animal models of SARS-CoV-2 infection will be developed for further in vivo testing of the inhibitors